Candel Therapeutics plans BLA submission by year-end for aglatimogen in prostate cancer
Candel Therapeutics said a pivotal phase III trial for aglatimogen in prostate cancer met its primary endpoint, supporting a planned BLA submission by year-end. The company expects new biomarker and long-term survivor data in Q3 and Q4.